Regulation of Circulating Progenitor Cells in Left Ventricular Dysfunction

Boilson, Barry A.; Larsen, Katarina; Harbuzariu, Adriana; Delacroix, Sinny; Kořínek, Josef; Froehlich, Harald; Bailey, Kent R.; Scott, Christopher G.; Shapiro, Brian P.; Boerrigter, Guido; Chen, Horng H.; Redfield, Margaret M.; Burnett, John C.; Simari, Robert D.

doi:10.1161/circheartfailure.109.879437

Cited by 8 publications

(5 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is possible that the cells that were enumerated by these groups were in fact a combination of EPCs and hematopoetic progenitor cells (HPCs). We demonstrated similar observations to other groups in patients with early and advanced coronary artery disease [ 32 , 33 ], and a canine model of heart failure [ 34 ], but application of stringent criteria regarding CD45 expression identified two distinct groups of CD34 + positive cells - a predominant CD34 + CD45dim VEGFR2-fraction (HPCs) and very rare CD34 + CD45- VEGFR2+ population (EPCs) [ 32 , 34 ]. Only the HPCs were demonstrated to be altered in number in the setting of cardiovascular disease.…”

Section: Literature Reviewsupporting

confidence: 85%

Differential phenotype and behavior in culture of CD34 positive cells from peripheral blood and adipose tissue

Froehlich

Simari

Boilson

2021

Heliyon

Self Cite

View full text Add to dashboard Cite

The localization and quantification of endothelial progenitor cells (EPCs) are controversial. Circulating CD34 + cells in blood have been identified as EPCs and as biomarkers of cardiovascular disease. We discuss in this paper the current data describing differential phenotype and behavior in vitro of CD34 positive cells from the circulation and adipose tissue (AT). We also describe in brief our own findings from CD34 + cells isolated from leukopheresis cones derived from healthy platelet donors and from patients undergoing bariatric surgery. We conclude that CD34 + cells in blood and in AT are different in antigenic profile and behavior in culture. The findings described assert that CD34 + cells detected in blood previously identified as biomarkers of cardiovascular disease are predominantly HPCs rather than EPCs, and that true CD34 + EPCs can be readily identified and extracted from AT, supportive of the current evidence which suggests EPCs are resident in the tissue vasculature.

show abstract

Section: Literature Reviewsupporting

confidence: 85%

Differential phenotype and behavior in culture of CD34 positive cells from peripheral blood and adipose tissue

Froehlich

Simari

Boilson

2021

Heliyon

Self Cite

View full text Add to dashboard Cite

show abstract

“…37 Indeed, 14% of younger patients (ages 50-64) in our study were screened as frail with CFS, supporting the theory that stressors associated with chronic HF may accelerate biological ageing processes. 38 Our findings expand on a growing literature base on the role of palliative care teams in the care of patients with advanced HF. Despite the increased recognition of the importance of palliative care referrals to address symptom management, goals of care conversations, and prognostic awareness, the types of assessments conducted and resultant interventions by palliative care teams remain varied.…”

Section: Discussionsupporting

confidence: 73%

“…However, our decision to expand eligibility criteria for frailty screening to patients 50 years and older addresses considerations specific to the HF population: frailty can be accelerated by the presence of underlying HF independent of age and NYHA classification, and the population of patients considered for advance heart therapies evaluations tend to be younger 37. Indeed, 14% of younger patients (ages 50–64) in our study were screened as frail with CFS, supporting the theory that stressors associated with chronic HF may accelerate biological ageing processes 38…”

Section: Discussionsupporting

confidence: 73%

Feasibility of frailty screening among patients with advanced heart failure

Lehto,

Jain,

Bernacki

et al. 2023

BMJ Open Qual

View full text Add to dashboard Cite

BackgroundFrailty is common among patients with advanced heart failure (HF), and screening for frailty to guide care is recommended. Although multiple tools are available to screen for frailty, the feasibility of routinely incorporating frailty screening into daily clinical practice among hospitalised advanced HF patients has not been rigorously tested.MethodsThis was a prospective, single-centre, quality improvement study. Two brief frailty screening tools were incorporated into palliative care consultations for all patients ≥50 years from August 2021 to October 2022. In the first phase, the Clinical Frailty Scale (CFS) was implemented, followed by the Study of Osteoporotic Fracture (SOF) tool or a modified SOF (mSOF) version in the second phase. The primary outcome was feasibility (%) of performing frailty screenings for this high-risk population.ResultsA total of 212 patients (mean age 69±10 years, 69% male, 79% white, 30% with ischaemic HF) were referred for palliative care consultation during the study period. Overall, frailty screens were completed in 86% (n=183) of patients. CFS and mSOF reached >80% of adoption, while SOF adoption was 54%. Altogether, 52% of the population screened frail by use of CFS and 52% also by mSOF. All clinicians (n=6) participating in the study reported that frailty screening tools were useful and acceptable, and 83% reported plans for continued utilisation in future clinical practice.ConclusionsFrailty screening with CFS or mSOF tools was feasible in hospitalised patients with advanced HF. Tools that require physical assessment were more challenging to implement. These data support the feasibility of incorporating questionnaire-based frailty screening in a busy hospital setting.

show abstract

“…At 0-, 3-and 6-week pacing, 1 ml whole blood was collected in EDTA tube to perform flow cytometry according to the previous study [22]. Cells were incubated for 30 min at 4 °C with CD34-PE antibody (eBiosciences, 12-0340), VEGFR-2-APC antibody (R&D Systems, FAB357A) and CD45-FITC (eBiosciences, 11-5450) at saturating concentrations.…”

Section: Quantification Of Circulating Epc Levelmentioning

confidence: 99%

Tachycardia pacing induces myocardial neovascularization and mobilizes circulating endothelial progenitor cells partly via SDF-1 pathway in canines

et al. 2014

View full text Add to dashboard Cite

Neovascularization plays pivotal role in ischemic heart failure; however, it is unclear in non-ischemic heart failure. Non-ischemic heart failure was induced by chronic rapid right ventricular pacing at 200 beats/min, respectively, for 3 and 6 weeks in 12 dogs. Sham-operation was performed in another 6 dogs as control. Three-week tachycardia pacing could induce mild/moderate heart failure and 6-week pacing could induce severe heart failure. Pan-microvessel density (MVD) was assessed by CD31 and neovascularization density was assessed by CD105. Mean CD31-MVD and CD105-MVD were significantly increased after 3-week pacing. However, CD105-MVD was significantly decreased by 80 % in 6-week pacing group compared with 3-week pacing group, whereas CD31-MVD was only decreased slightly (15 %; P < 0.05). Myocardial proangiogenic factor stromal cell-derived factor 1 (SDF-1), hypoxia-inducible factors 1α (HIF-1α, a transcription factor which could regulate SDF-1 expression), serum SDF-1 levels and circulating EPC mobilization were greatly elevated after 3-week pacing but nearly returned to baseline level after 6-week pacing, which were in accordance with the changes of neovascularization levels assessed by CD105. Angiogenesis and migrating ability of EPCs were enhanced after stimulation of SDF-1, which could be abolished by pretreatment with SDF-1 receptor antagonist AMD3100. In addition, angiogenesis and migrating functions of EPCs were significantly enhanced by the serum from 3-week pacing dogs, but had much weaker response to the serum from 6-week pacing dogs. In conclusion, tachycardia pacing-induced non-ischemic heart failure, promoted myocardial neovascularization and mobilized circulating EPCs, which might be mediated partly through SDF-1 pathway.

show abstract

Regulation of Circulating Progenitor Cells in Left Ventricular Dysfunction

Cited by 8 publications

References 42 publications

Differential phenotype and behavior in culture of CD34 positive cells from peripheral blood and adipose tissue

Differential phenotype and behavior in culture of CD34 positive cells from peripheral blood and adipose tissue

Feasibility of frailty screening among patients with advanced heart failure

Tachycardia pacing induces myocardial neovascularization and mobilizes circulating endothelial progenitor cells partly via SDF-1 pathway in canines

Contact Info

Product

Resources

About